DE3704825A1 - Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung - Google Patents
Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendungInfo
- Publication number
- DE3704825A1 DE3704825A1 DE19873704825 DE3704825A DE3704825A1 DE 3704825 A1 DE3704825 A1 DE 3704825A1 DE 19873704825 DE19873704825 DE 19873704825 DE 3704825 A DE3704825 A DE 3704825A DE 3704825 A1 DE3704825 A1 DE 3704825A1
- Authority
- DE
- Germany
- Prior art keywords
- prostaglandin
- derivatives
- compounds
- pge1
- derivatives according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003165 prostaglandin E1 derivatives Chemical class 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 title abstract description 8
- 229940126601 medicinal product Drugs 0.000 title description 3
- 239000013543 active substance Substances 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 7
- 206010040943 Skin Ulcer Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 3
- 206010018852 Haematoma Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 description 15
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 13
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ROUDCKODIMKLNO-CTBSXBMHSA-N 6-oxoprostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(O)=O ROUDCKODIMKLNO-CTBSXBMHSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WLXALCKAKGDNAT-UHFFFAOYSA-N diazoethane Chemical compound CC=[N+]=[N-] WLXALCKAKGDNAT-UHFFFAOYSA-N 0.000 description 4
- ROUDCKODIMKLNO-UHFFFAOYSA-N 6-oxo-PGE1 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC(=O)CCCCC(O)=O ROUDCKODIMKLNO-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- LVDCZROIKIHUKJ-QZCLESEGSA-N ethyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OCC LVDCZROIKIHUKJ-QZCLESEGSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010060964 Arterial haemorrhage Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873704825 DE3704825A1 (de) | 1987-02-16 | 1987-02-16 | Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung |
| DE88102189T DE3874610D1 (OSRAM) | 1987-02-16 | 1988-02-15 | |
| JP63032571A JPS63246331A (ja) | 1987-02-16 | 1988-02-15 | プロスタグランジンｅ↓１誘導体含有医薬組成物 |
| DK198800775A DK173552B1 (da) | 1987-02-16 | 1988-02-15 | Anvendelse af prostaglandin-E1-derivater til fremstilling af farmaceutiske præparater til transkutan indgift |
| AT88102189T ATE80616T1 (de) | 1987-02-16 | 1988-02-15 | Prostaglandin e1-derivate und ihre therapeutische anwendung. |
| ES88102189T ES2043696T3 (es) | 1987-02-16 | 1988-02-15 | Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea. |
| EP88102189A EP0292643B1 (de) | 1987-02-16 | 1988-02-15 | Prostaglandin E1-Derivate und ihre therapeutische Anwendung |
| HU88742A HU199687B (en) | 1987-02-16 | 1988-02-16 | Process for producing transcutane pharmaceutical compositions containing e1 prostaglandin derivatives |
| AU11766/88A AU623336B2 (en) | 1987-02-16 | 1988-02-16 | Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives |
| ZA881053A ZA881053B (en) | 1987-02-16 | 1988-02-16 | Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration |
| CA000559004A CA1327359C (en) | 1987-02-16 | 1988-02-16 | Prostaglandin el derivatives as pharmacologically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
| US07/483,995 US5219885A (en) | 1987-02-16 | 1990-02-22 | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
| AU15184/92A AU649130B2 (en) | 1987-02-16 | 1992-04-24 | Pharmaceutical compositions for transcutaneous administration |
| GR920402069T GR3005743T3 (OSRAM) | 1987-02-16 | 1992-09-17 | |
| US08/044,511 US5464868A (en) | 1987-02-16 | 1993-04-07 | Prostaglandin E1 derivatives for transdermal administration and methods of treatment therewith |
| US08/550,906 US5681850A (en) | 1987-02-16 | 1995-10-31 | Method of treatment of impotence with prostaglandin E1 derivatives |
| US08/874,223 US5973002A (en) | 1987-02-16 | 1997-06-13 | Prostaglandin E1 derivatives as pharmacologically active agents, especially for transcutaneous administration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873704825 DE3704825A1 (de) | 1987-02-16 | 1987-02-16 | Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3704825A1 true DE3704825A1 (de) | 1988-08-25 |
Family
ID=6321070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19873704825 Withdrawn DE3704825A1 (de) | 1987-02-16 | 1987-02-16 | Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung |
| DE88102189T Expired - Lifetime DE3874610D1 (OSRAM) | 1987-02-16 | 1988-02-15 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE88102189T Expired - Lifetime DE3874610D1 (OSRAM) | 1987-02-16 | 1988-02-15 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0292643B1 (OSRAM) |
| JP (1) | JPS63246331A (OSRAM) |
| AT (1) | ATE80616T1 (OSRAM) |
| AU (2) | AU623336B2 (OSRAM) |
| CA (1) | CA1327359C (OSRAM) |
| DE (2) | DE3704825A1 (OSRAM) |
| DK (1) | DK173552B1 (OSRAM) |
| ES (1) | ES2043696T3 (OSRAM) |
| GR (1) | GR3005743T3 (OSRAM) |
| HU (1) | HU199687B (OSRAM) |
| ZA (1) | ZA881053B (OSRAM) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0638312A4 (en) * | 1993-02-03 | 1995-07-26 | Teijin Ltd | DERMATOLOGICAL PREPARATION WITH ISOCARBACYCLIN AS AN ACTIVE INGREDIENT. |
| EP0634172A4 (en) * | 1993-02-03 | 1995-08-02 | Teijin Ltd | COMPOSITION FOR DERMATOLOGICAL PREPARATION CONTAINING PROSTACYCLINE AS ACTIVE INGREDIENT. |
| US6007836A (en) * | 1993-05-28 | 1999-12-28 | Vericade, Inc. | Transdermal vasodilator |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2939569A (en) * | 1957-10-16 | 1960-06-07 | Gay W Roach | Cotton weighing machine |
| FR2812191B1 (fr) * | 2000-07-28 | 2003-10-17 | Oreal | Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques |
| FR2812192B1 (fr) * | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
| FR2812190B1 (fr) * | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
| FR2812193B1 (fr) * | 2000-07-28 | 2003-10-24 | Oreal | Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques |
| AU2004227853A1 (en) * | 2003-04-02 | 2004-10-21 | Nexmed (Holdings), Inc. | Prostaglandin compositions and their use for the treatment of vasospasm |
| IT1402047B1 (it) * | 2010-10-19 | 2013-08-28 | Cross Pharma Sa | Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali |
| US8940794B2 (en) | 2011-04-07 | 2015-01-27 | Nexmed Holdings, Inc. | Methods and compositions for treating Raynaud's disease |
| US10383839B2 (en) | 2011-06-30 | 2019-08-20 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
| ITRM20120036A1 (it) * | 2012-02-02 | 2013-08-03 | Robert Davis Steigerwalt Jr | Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2753986A1 (de) * | 1976-12-30 | 1978-07-06 | Upjohn Co | Prostaglandin e-artige derivate und analoga mit 6-ketofunktion und verfahren zu deren herstellung |
| DE2840032A1 (de) * | 1977-09-16 | 1979-03-29 | Ono Pharmaceutical Co | Prostaglandin-analoge |
| US4205178A (en) * | 1976-12-30 | 1980-05-27 | The Upjohn Company | 6-Keto prostaglandin E-type compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3735005A (en) * | 1970-08-19 | 1973-05-22 | Alza Corp | Method for preparing a viable platelet concentrate |
| JPS59216820A (ja) * | 1983-05-20 | 1984-12-06 | Taisho Pharmaceut Co Ltd | プロスタグランジン脂肪乳剤 |
| US4707495A (en) * | 1985-10-28 | 1987-11-17 | Ortho Pharmaceutical | Peptic ulcer treatment method |
-
1987
- 1987-02-16 DE DE19873704825 patent/DE3704825A1/de not_active Withdrawn
-
1988
- 1988-02-15 EP EP88102189A patent/EP0292643B1/de not_active Expired - Lifetime
- 1988-02-15 DE DE88102189T patent/DE3874610D1/de not_active Expired - Lifetime
- 1988-02-15 JP JP63032571A patent/JPS63246331A/ja active Pending
- 1988-02-15 ES ES88102189T patent/ES2043696T3/es not_active Expired - Lifetime
- 1988-02-15 AT AT88102189T patent/ATE80616T1/de not_active IP Right Cessation
- 1988-02-15 DK DK198800775A patent/DK173552B1/da not_active IP Right Cessation
- 1988-02-16 AU AU11766/88A patent/AU623336B2/en not_active Ceased
- 1988-02-16 HU HU88742A patent/HU199687B/hu not_active IP Right Cessation
- 1988-02-16 CA CA000559004A patent/CA1327359C/en not_active Expired - Fee Related
- 1988-02-16 ZA ZA881053A patent/ZA881053B/xx unknown
-
1992
- 1992-04-24 AU AU15184/92A patent/AU649130B2/en not_active Ceased
- 1992-09-17 GR GR920402069T patent/GR3005743T3/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2753986A1 (de) * | 1976-12-30 | 1978-07-06 | Upjohn Co | Prostaglandin e-artige derivate und analoga mit 6-ketofunktion und verfahren zu deren herstellung |
| US4205178A (en) * | 1976-12-30 | 1980-05-27 | The Upjohn Company | 6-Keto prostaglandin E-type compounds |
| DE2840032A1 (de) * | 1977-09-16 | 1979-03-29 | Ono Pharmaceutical Co | Prostaglandin-analoge |
Non-Patent Citations (4)
| Title |
|---|
| DE-Z: A.Creutzig, Prostaglandine und Gefäßer- krankungen, Med.Klinik 81, 11, 1986, S.395-399 * |
| DE-Z: A.K.Sim u.a., Arzneim.-Forsch./Drug Res.36 (II) Nr.8, 1986, S.1206-1209 * |
| DE-Z: P.Demol u.a., Arzneim.-Forsch./Drug Res.36 (II) Nr.9, 1986, S.1406-1408 * |
| GB-Z: U.Förstermann and B.Neufang, J.Pharm.Pharma-col.1983, 35, S.724-728 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0638312A4 (en) * | 1993-02-03 | 1995-07-26 | Teijin Ltd | DERMATOLOGICAL PREPARATION WITH ISOCARBACYCLIN AS AN ACTIVE INGREDIENT. |
| EP0634172A4 (en) * | 1993-02-03 | 1995-08-02 | Teijin Ltd | COMPOSITION FOR DERMATOLOGICAL PREPARATION CONTAINING PROSTACYCLINE AS ACTIVE INGREDIENT. |
| US5530027A (en) * | 1993-02-03 | 1996-06-25 | Teijin Limited | External skin treatment agent composition containing prostacyclins as active ingredient |
| US6007836A (en) * | 1993-05-28 | 1999-12-28 | Vericade, Inc. | Transdermal vasodilator |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0292643A1 (de) | 1988-11-30 |
| HUT46224A (en) | 1988-10-28 |
| DK77588A (da) | 1988-08-17 |
| JPS63246331A (ja) | 1988-10-13 |
| DK173552B1 (da) | 2001-02-26 |
| GR3005743T3 (OSRAM) | 1993-06-07 |
| DE3874610D1 (OSRAM) | 1992-10-22 |
| CA1327359C (en) | 1994-03-01 |
| ATE80616T1 (de) | 1992-10-15 |
| DK77588D0 (da) | 1988-02-15 |
| ZA881053B (en) | 1988-08-12 |
| AU1518492A (en) | 1992-06-25 |
| AU649130B2 (en) | 1994-05-12 |
| ES2043696T3 (es) | 1994-01-01 |
| AU623336B2 (en) | 1992-05-14 |
| EP0292643B1 (de) | 1992-09-16 |
| AU1176688A (en) | 1988-08-18 |
| HU199687B (en) | 1990-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5973002A (en) | Prostaglandin E1 derivatives as pharmacologically active agents, especially for transcutaneous administration | |
| EP0259468B1 (de) | Cyclodextrinclathrate von carbacyclinderivaten und ihre verwendung als arzneimittel | |
| CH637949A5 (en) | Process for the preparation of novel sodium salts of prostaglandin derivatives | |
| DE3704825A1 (de) | Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung | |
| DE69528291T2 (de) | Nicht-beta oxidierbare fettsäureanaloge,deren verwendung als therapeutisch wirksame medikamente sowie deren herstellung | |
| DE3315356A1 (de) | Verwendung von prostaglandinanalogen | |
| DE69512929T2 (de) | Salze von aminoalkoholen und diese enthaltende pharmazeutische zusammensetzungen | |
| EP0734723A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| DE60011748T2 (de) | Methoden und zusammenstellungen zur behandlung der weiblichen sexuellen dysfunktion | |
| DE3310556A1 (de) | Verwendung von prostaglandinanalogen | |
| DE2611183A1 (de) | Stabile dosierungsform von prostaglandinartigen verbindungen | |
| CH638510A5 (de) | Prostacyclinanaloga. | |
| WO1986004504A1 (en) | 9-halogen prostaglandine clathrates and utilization thereof as drugs | |
| DE3740838A1 (de) | Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel | |
| EP0656889B1 (de) | 9-chlor-prostaglandin-ester und -amide und ihre verwendung für die herstellung von arzneimitteln | |
| DE4201942A1 (de) | Phenonverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| DE2720998A1 (de) | Cyclische aether, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate | |
| JP2550176B2 (ja) | イソカルバサイクリン誘導体を活性成分として含有する糖尿病性神経症治療剤 | |
| DE69313521T2 (de) | PGE1-Analoge | |
| DE1956290A1 (de) | Neue,prostaglandinartige Verbindungen und Verfahren zu ihrer Herstellung | |
| DE2705613A1 (de) | Bicycloalkylderivate von prostaglandinen | |
| DE2632951A1 (de) | Neue 1-deoxy-2,3-0-alkyliden-ribofuranuronsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE3320544A1 (de) | Polyprenylverbindungen, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
| DE3146278C2 (de) | cis-Bicyclo[3.3.0]octanderivate, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser Verbindungen | |
| DE4124695A1 (de) | Carbacyclinderivate als mittel zur behandlung von psoriasis vulgaris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8141 | Disposal/no request for examination |